Wikidata |

Wikidata

Matches in Wikidata for { <http://www.wikidata.org/entity/Q59336540> ?p ?o ?g. }

Showing items 1 to 100 of ±106 with 100 items per page.

Q59336540 description "artículu científicu espublizáu en payares de 2018" @default.
Q59336540 description "im November 2018 veröffentlichter wissenschaftlicher Artikel" @default.
Q59336540 description "scientific article published on 19 November 2018" @default.
Q59336540 description "wetenschappelijk artikel" @default.
Q59336540 description "наукова стаття, опублікована в листопаді 2018" @default.
Q59336540 name "Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)" @default.
Q59336540 name "Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)" @default.
Q59336540 type Item @default.
Q59336540 label "Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)" @default.
Q59336540 label "Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)" @default.
Q59336540 prefLabel "Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)" @default.
Q59336540 prefLabel "Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)" @default.
Q59336540 P1433 Q59336540-D236652B-0A54-4E6C-A302-439F8AA041E4 @default.
Q59336540 P1476 Q59336540-10F8D08D-1F5D-43E3-920D-69EE62FF080B @default.
Q59336540 P2093 Q59336540-036D60A6-2BD8-4DCF-BDC1-CBB40E9B83EF @default.
Q59336540 P2093 Q59336540-364CB447-EB7E-48BE-89BC-F336C13B3CFC @default.
Q59336540 P2093 Q59336540-496E1143-FD68-41F3-BC8B-18DDB7CF3B3D @default.
Q59336540 P2093 Q59336540-732F899F-B5CB-4263-9D85-92434365E529 @default.
Q59336540 P2093 Q59336540-9A1A151E-2301-4015-AF83-9FB0871C893F @default.
Q59336540 P2093 Q59336540-9BFFDA54-72BA-4DCF-BA50-C17727E3018B @default.
Q59336540 P2093 Q59336540-A69D2ED0-15A2-43B6-870D-808B65D9EAC1 @default.
Q59336540 P275 Q59336540-13eb1e91-71b8-4a9e-8d90-31bdf9d412ab @default.
Q59336540 P2860 Q59336540-1076EA7F-EFA7-4128-A9E8-90BA2BF2E642 @default.
Q59336540 P2860 Q59336540-135F893E-6124-4D29-B3FD-638CEDAB6D11 @default.
Q59336540 P2860 Q59336540-1B84A0A3-5A8D-4503-8CE7-ED3D7D468590 @default.
Q59336540 P2860 Q59336540-1C7A3788-92C4-463A-A16F-116CCBFFDFD2 @default.
Q59336540 P2860 Q59336540-4DC304A1-5C88-4E70-A056-D7DCE6929AD6 @default.
Q59336540 P2860 Q59336540-53F3FF72-AF8F-44A2-848B-3ABFCB51C7D4 @default.
Q59336540 P2860 Q59336540-54CB5AF1-05B0-4D3F-A79E-BBF8BF559764 @default.
Q59336540 P2860 Q59336540-56AAFC86-C79B-4098-9984-E07366F83577 @default.
Q59336540 P2860 Q59336540-5C0E954B-EAB4-4501-9D22-BDE6F549745D @default.
Q59336540 P2860 Q59336540-5C54256F-47EB-4FD8-B123-9D33DE4666CA @default.
Q59336540 P2860 Q59336540-5D173E74-0CD3-4318-945D-E09EA7366A40 @default.
Q59336540 P2860 Q59336540-70812CD9-523A-4FFC-95F8-9594A1BDED0B @default.
Q59336540 P2860 Q59336540-76967BA0-EA23-41C2-B058-24ACA56AD9E4 @default.
Q59336540 P2860 Q59336540-91E87F34-8F5C-458B-947E-6B3EFA238FC1 @default.
Q59336540 P2860 Q59336540-A7871856-09DA-4BB9-A593-987F7A262DF1 @default.
Q59336540 P2860 Q59336540-AB36F476-2DF5-43C2-8DDD-F95C6BEB9E0B @default.
Q59336540 P2860 Q59336540-BF2726B2-48EC-4911-98B6-E758FF9DCE8E @default.
Q59336540 P2860 Q59336540-C0AA7909-54B8-4EC4-8DD6-8A9756AFB27E @default.
Q59336540 P2860 Q59336540-DB6317DF-0581-49BF-8A40-C896573C9BB1 @default.
Q59336540 P2860 Q59336540-EF5B3463-E1A6-42F1-A3C2-85B21C4C0409 @default.
Q59336540 P2888 Q59336540-B819DBA9-27CC-4750-ACC8-D844F34046D7 @default.
Q59336540 P304 Q59336540-604EB396-1D32-4099-9873-3615D722DE62 @default.
Q59336540 P31 Q59336540-29172ABF-8859-4B10-89A2-B57459595A06 @default.
Q59336540 P356 Q59336540-94432F74-69B0-418D-844F-D541FB4FF358 @default.
Q59336540 P407 Q59336540-BB3A737E-99B0-4C7E-B529-66B1F4CBFA2B @default.
Q59336540 P433 Q59336540-871200CE-8671-473A-9F57-FB64EB3884C4 @default.
Q59336540 P478 Q59336540-C43F0731-7BF3-4788-B10D-1CE80B020187 @default.
Q59336540 P50 Q59336540-3B3FEE83-5A06-4F4F-8C97-A3ABE0E6A986 @default.
Q59336540 P577 Q59336540-30C8BD53-D8AE-45D1-B54C-37B265223008 @default.
Q59336540 P6179 Q59336540-BB35A1C9-A033-4181-B032-0FCCB9FD0614 @default.
Q59336540 P6216 Q59336540-0c659692-d006-4dad-b0e4-bc700b837423 @default.
Q59336540 P698 Q59336540-D2F83BA3-5844-4AD3-9FE5-09A192DC5D10 @default.
Q59336540 P921 Q59336540-2E40EEE1-5575-489A-AA3B-3206901ACD43 @default.
Q59336540 P921 Q59336540-2F8E112F-77B7-490F-835B-E5A86302913A @default.
Q59336540 P921 Q59336540-CAF9341C-7F1A-495F-A137-17AAEE97A4C8 @default.
Q59336540 P932 Q59336540-7BCA7626-4C86-4584-9DB1-AACF59F4F672 @default.
Q59336540 P356 S12885-018-5045-7 @default.
Q59336540 P698 30453910 @default.
Q59336540 P1433 Q326300 @default.
Q59336540 P1476 "Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)" @default.
Q59336540 P2093 "Gabriele Ihorst" @default.
Q59336540 P2093 "Hartmut Bertz" @default.
Q59336540 P2093 "Justus Duyster" @default.
Q59336540 P2093 "Jürgen Finke" @default.
Q59336540 P2093 "Nadine Röthling" @default.
Q59336540 P2093 "Olga Grishina" @default.
Q59336540 P2093 "Robert Zeiser" @default.
Q59336540 P275 Q20007257 @default.
Q59336540 P2860 Q24563701 @default.
Q59336540 P2860 Q24626051 @default.
Q59336540 P2860 Q30994673 @default.
Q59336540 P2860 Q33391880 @default.
Q59336540 P2860 Q33399980 @default.
Q59336540 P2860 Q34420372 @default.
Q59336540 P2860 Q34474243 @default.
Q59336540 P2860 Q36862931 @default.
Q59336540 P2860 Q37641063 @default.
Q59336540 P2860 Q38179308 @default.
Q59336540 P2860 Q41099517 @default.
Q59336540 P2860 Q41908710 @default.
Q59336540 P2860 Q43136155 @default.
Q59336540 P2860 Q43170920 @default.
Q59336540 P2860 Q45164619 @default.
Q59336540 P2860 Q49679320 @default.
Q59336540 P2860 Q53676885 @default.
Q59336540 P2860 Q58814216 @default.
Q59336540 P2860 Q83468020 @default.
Q59336540 P2860 Q87635679 @default.
Q59336540 P2888 s12885-018-5045-7 @default.
Q59336540 P304 "1132" @default.
Q59336540 P31 Q13442814 @default.
Q59336540 P356 "10.1186/S12885-018-5045-7" @default.
Q59336540 P407 Q1860 @default.
Q59336540 P433 "1" @default.
Q59336540 P478 "18" @default.
Q59336540 P50 Q87841821 @default.
Q59336540 P577 "2018-11-19T00:00:00Z" @default.
Q59336540 P6179 "1110032962" @default.